Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 56 min ago
Peer-reviewedCC BYMicrobiome

Adjuvant commensal therapy enhances antibiotic efficacy against Staphylococcus aureus.

1 more authors
4 affiliations
  1. 1Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  2. 2Institute of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  3. 3Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.
  4. 4Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. [email protected].

Abstract

Background

Staphylococcus aureus is a common human pathobiont whose nasal colonization represents a major risk factor for subsequent infection. The prevalence of antimicrobial resistance, coupled with antibiotic-induced microbiota perturbation, has rendered S. aureus-associated infections increasingly difficult to treat. Commensal bacteria have emerged as potential modulators of both host immune responses and pathogen pathogenesis; however, whether they can act as therapeutic adjuvants to enhance treatment outcomes in S. aureus-associated infections remains unclear. Here, we assess the efficacy of commensal bacteria as an adjuvant therapeutic strategy.Results

Using A549 Dual™ reporter cells, we demonstrate that commensals and pathobionts elicit distinct activation profiles of NF-κB and interferon regulatory factor (IRF) signaling pathways and differential IL-8 production. In a 3D humanized airway tissue model, D. pigrum significantly enhanced antibiotic-mediated reduction of S. aureus survival relative to antibiotic treatment alone (D. pigrum KPL1914: 37.3% reduction, 95% CI 2.0-72.6%, Padj = 0.0340; D. pigrum AMBR11: 48.1% reduction, 95% CI 2.3-93.9%, Padj = 0.0356), while preserving barrier integrity and augmenting pro-inflammatory cytokine responses. However, the loss of efficacy with heat-killed D. pigrum indicates that viable bacteria and active host- and/or pathobiont-directed interactions are required to mediate its anti-S. aureus effects. Dual RNA-seq transcriptomic analysis revealed enrichment of host inflammatory pathways and reduction of S. aureus pathogenic potential during D. pigrum antibiotic adjuvant treatment in the airway tissue model. Furthermore, co-culture experiments revealed that D. pigrum constrains core metabolic pathways in S. aureus.Conclusions

These findings demonstrate that D. pigrum limits S. aureus through both host immune modulation and direct suppression of bacterial pathogenesis and adaptive fitness, supporting its potential as a microbiota-based therapeutic adjuvant to enhance antibiotic efficacy against S. aureus-associated infections. Video Abstract.

Related

  1. 4-Hydroxycoumarin inhibits biofilm formation and enhances antibiotic efficacy against Escherichia coli O157:H7
    Hongxing Zhang, Jing Xu, Yaxin Zhou +5
    Frontiers in microbiologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCCrossref
  2. Adjuvant Effect of Meldrum’s Acid Derivatives on Antibiotic Activity Against Multidrug-Resistant Bacteria
    Isaac Moura Araújo, Ewerton Yago de Sousa Rodrigues, Daniel Sampaio Alves +18
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral biochemistryEurope PMC
  3. Pseudomonas aeruginosa modulates Staphylococcus aureus biofilm formation and antibiotic resistance
    Zeinab M. Helal, Soha Lotfy Elshaer, Mohammed El-Mowafy +1
    Scientific ReportsPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationCrossrefDOAJ
  4. Aurora A exacerbates antibiotic-resistant Staphylococcus aureus infection through ASC phosphorylation
    Hajime Yamauchi, Kei Sakamoto, Yasuyuki Matsuda +14
    EMBO ReportsPeer-reviewedCC BYFull textMolecular biology & gene regulationDOAJ
  5. Quorum sensing inhibitor-antibiotic conjugate suppresses virulence and eradicates intracellular Staphylococcus aureus.
    Meiling Ma, Shihao Luo, Junshu Wang +6
    Pharmaceutical science advancesPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
BibTeX
@article{chang2026adjuvant,
  title = {{Adjuvant commensal therapy enhances antibiotic efficacy against Staphylococcus aureus.}},
  author = {Chun-Chi Chang and Tomas Demeter and Alejandro Gómez-Mejia and Weronika Barcik and Judith Bergada-Pijuan and Andrew G Kempchinsky and Umberto Maccio and Eline Cauwenberghs and Nora Ranzoni and Ilke De Boeck and Sarah Lebeer and Srikanth Mairpady Shambat and Silvio D Brugger},
  journal = {Microbiome},
  year = {2026},
  month = aug,
  doi = {10.1186/s40168-026-02479-6},
  url = {https://europepmc.org/article/MED/43010108},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Adjuvant commensal therapy enhances antibiotic efficacy against Staphylococcus aureus.
AU  - Chun-Chi Chang
AU  - Tomas Demeter
AU  - Alejandro Gómez-Mejia
AU  - Weronika Barcik
AU  - Judith Bergada-Pijuan
AU  - Andrew G Kempchinsky
AU  - Umberto Maccio
AU  - Eline Cauwenberghs
AU  - Nora Ranzoni
AU  - Ilke De Boeck
AU  - Sarah Lebeer
AU  - Srikanth Mairpady Shambat
AU  - Silvio D Brugger
PY  - 2026
DA  - 2026/08/14
JO  - Microbiome
DO  - 10.1186/s40168-026-02479-6
UR  - https://europepmc.org/article/MED/43010108
AB  - Background  Staphylococcus aureus is a common human pathobiont whose nasal colonization represents a major risk factor for subsequent infection. The prevalence of antimicrobial resistance, coupled with antibiotic-induced microbiota perturbation, has rendered S. aureus-associated infections increasingly difficult to treat. Commensal bacteria have emerged as potential modulators of both host immune responses and pathogen pathogenesis; however, whether they can act as therapeutic adjuvants to enhance treatment outcomes in S. aureus-associated infections remains unclear. Here, we assess the efficacy of commensal bacteria as an adjuvant therapeutic strategy.Results  Using A549 Dual™ reporter cells, we demonstrate that commensals and pathobionts elicit distinct activation profiles of NF-κB and interferon regulatory factor (IRF) signaling pathways and differential IL-8 production. In a 3D humanized airway tissue model, D. pigrum significantly enhanced antibiotic-mediated reduction of S. aureus survival relative to antibiotic treatment alone (D. pigrum KPL1914: 37.3% reduction, 95% CI 2.0-72.6%, Padj = 0.0340; D. pigrum AMBR11: 48.1% reduction, 95% CI 2.3-93.9%, Padj = 0.0356), while preserving barrier integrity and augmenting pro-inflammatory cytokine responses. However, the loss of efficacy with heat-killed D. pigrum indicates that viable bacteria and active host- and/or pathobiont-directed interactions are required to mediate its anti-S. aureus effects. Dual RNA-seq transcriptomic analysis revealed enrichment of host inflammatory pathways and reduction of S. aureus pathogenic potential during D. pigrum antibiotic adjuvant treatment in the airway tissue model. Furthermore, co-culture experiments revealed that D. pigrum constrains core metabolic pathways in S. aureus.Conclusions  These findings demonstrate that D. pigrum limits S. aureus through both host immune modulation and direct suppression of bacterial pathogenesis and adaptive fitness, supporting its potential as a microbiota-based therapeutic adjuvant to enhance antibiotic efficacy against S. aureus-associated infections. Video Abstract.
SN  - 2049-2618
ER  -